LYMPHOMA SURVIVORSHIP AND CARDIOVASCULAR DISEASES SURVEILLANCE
(Abstract release date: 05/19/16)
EHA Library. Simula M. 06/09/16; 134758; PB1858
Dr. Maria Pina Simula
Contributions
Contributions
Abstract
Abstract: PB1858
Type: Publication Only
Background
Improvements in the treatment of Lymphomas have resulted in an increasing number of long term survivors. This patient’s population is at risk of developing late therapy related complications that can negatively affect their survival and quality of life.
Aims
In our institution since September 2014 the Hodgkin’s (HL) and aggressive non Hodgkin’s Lymphomas (nHL) long term survivors are followed up in a dedicated clinic aimed to detect long term clinical problems that can affect people undergone previous radiation therapy and/or chemotherapy.
Methods
We had planned electrocardiographic and echocardiografic evaluation in patients without known cardiological problems.
Results
We have analyzed data regarding consecutive 469 patients coming in our clinic from 15 September 2014 to 18 February 2016, 247 have been treated for HL and 222 for nHL. Two hundred thirty three were females, 236 males; median of age at diagnosis was 29 years for HL (13-84), 48 years for nHL (12-83); median of age at last observation in the follow up clinic was 50 years for HL (range 21-89) and 62 years for nHL (range 24-88). The median of duration of follow up was 18 years for HL (range 5-40) and 13 years for nHL (range 5-37). Thirty seven of our patients had cardiovascular disorders before the diagnosis of lymphoma.The cardiac function has been studied in three hundred sixty one of our patients.Two hundred twenty five out of 361 (62%) developed cardiac abnormalities of different type and severity in the period following treatment for their lymphoma (Table 1). They were 124 females (55%) and 101 males; 126 had previous HL ( 56%) and 99 nHL.The median age at cardiovascular disease detection was 54 years (range 20-83). The median time between diagnosis of lymphoma and diagnosis of cardiovascular diseases was 14 years (range 0-43).The most common cardiac disturbances described were valvulopathies of different type and grade (95), arterial hypertension (76) and ischemic cardiopathy (32); some patients had more than one alteration. Moreover 77 out patients showed a diastolic relaxation abnormality without ventricular dysfunction which whose the only alteration detected in 33 cases.In 114 patient abnormalities were first detected during screening in asymptomatic condition: in fact we had planned electrocardiographic and echocardiografic evaluation in 206 patients without known cardiological problems.One hundred fourteen out of 206 screened (55%) showed previous unknown cardiac disturbance.Regarding the previous therapies: mediastinal radiotherapy had been administered in 64 of patients with valvulopathies (and in all with only calcification) (67%), in 13 with ischemic cardiopathies (41%) and in 33 with diastolic relaxation abnormality (43%); chemotherapy antracycline-based had been receveid by 77 with valvulopathies (81%), by 19 with ischemic cardiopathies (60%) and by 73 with diastolic relaxation abnormality (95%).
Conclusion
Our analysis confirms that a high percentage of patient survived to lymphomas can develop cardiovascular diseases and outline the importance of cardiac surveillance.Their monitoring would be promote because can detect asymptomatic structural and functional anomalies as diastolic relaxation abnormality considered an early sign of cardiomyopathies.
Session topic: E-poster
Type: Publication Only
Background
Improvements in the treatment of Lymphomas have resulted in an increasing number of long term survivors. This patient’s population is at risk of developing late therapy related complications that can negatively affect their survival and quality of life.
Aims
In our institution since September 2014 the Hodgkin’s (HL) and aggressive non Hodgkin’s Lymphomas (nHL) long term survivors are followed up in a dedicated clinic aimed to detect long term clinical problems that can affect people undergone previous radiation therapy and/or chemotherapy.
Methods
We had planned electrocardiographic and echocardiografic evaluation in patients without known cardiological problems.
Results
We have analyzed data regarding consecutive 469 patients coming in our clinic from 15 September 2014 to 18 February 2016, 247 have been treated for HL and 222 for nHL. Two hundred thirty three were females, 236 males; median of age at diagnosis was 29 years for HL (13-84), 48 years for nHL (12-83); median of age at last observation in the follow up clinic was 50 years for HL (range 21-89) and 62 years for nHL (range 24-88). The median of duration of follow up was 18 years for HL (range 5-40) and 13 years for nHL (range 5-37). Thirty seven of our patients had cardiovascular disorders before the diagnosis of lymphoma.The cardiac function has been studied in three hundred sixty one of our patients.Two hundred twenty five out of 361 (62%) developed cardiac abnormalities of different type and severity in the period following treatment for their lymphoma (Table 1). They were 124 females (55%) and 101 males; 126 had previous HL ( 56%) and 99 nHL.The median age at cardiovascular disease detection was 54 years (range 20-83). The median time between diagnosis of lymphoma and diagnosis of cardiovascular diseases was 14 years (range 0-43).The most common cardiac disturbances described were valvulopathies of different type and grade (95), arterial hypertension (76) and ischemic cardiopathy (32); some patients had more than one alteration. Moreover 77 out patients showed a diastolic relaxation abnormality without ventricular dysfunction which whose the only alteration detected in 33 cases.In 114 patient abnormalities were first detected during screening in asymptomatic condition: in fact we had planned electrocardiographic and echocardiografic evaluation in 206 patients without known cardiological problems.One hundred fourteen out of 206 screened (55%) showed previous unknown cardiac disturbance.Regarding the previous therapies: mediastinal radiotherapy had been administered in 64 of patients with valvulopathies (and in all with only calcification) (67%), in 13 with ischemic cardiopathies (41%) and in 33 with diastolic relaxation abnormality (43%); chemotherapy antracycline-based had been receveid by 77 with valvulopathies (81%), by 19 with ischemic cardiopathies (60%) and by 73 with diastolic relaxation abnormality (95%).
Conclusion
Our analysis confirms that a high percentage of patient survived to lymphomas can develop cardiovascular diseases and outline the importance of cardiac surveillance.Their monitoring would be promote because can detect asymptomatic structural and functional anomalies as diastolic relaxation abnormality considered an early sign of cardiomyopathies.
Session topic: E-poster
Abstract: PB1858
Type: Publication Only
Background
Improvements in the treatment of Lymphomas have resulted in an increasing number of long term survivors. This patient’s population is at risk of developing late therapy related complications that can negatively affect their survival and quality of life.
Aims
In our institution since September 2014 the Hodgkin’s (HL) and aggressive non Hodgkin’s Lymphomas (nHL) long term survivors are followed up in a dedicated clinic aimed to detect long term clinical problems that can affect people undergone previous radiation therapy and/or chemotherapy.
Methods
We had planned electrocardiographic and echocardiografic evaluation in patients without known cardiological problems.
Results
We have analyzed data regarding consecutive 469 patients coming in our clinic from 15 September 2014 to 18 February 2016, 247 have been treated for HL and 222 for nHL. Two hundred thirty three were females, 236 males; median of age at diagnosis was 29 years for HL (13-84), 48 years for nHL (12-83); median of age at last observation in the follow up clinic was 50 years for HL (range 21-89) and 62 years for nHL (range 24-88). The median of duration of follow up was 18 years for HL (range 5-40) and 13 years for nHL (range 5-37). Thirty seven of our patients had cardiovascular disorders before the diagnosis of lymphoma.The cardiac function has been studied in three hundred sixty one of our patients.Two hundred twenty five out of 361 (62%) developed cardiac abnormalities of different type and severity in the period following treatment for their lymphoma (Table 1). They were 124 females (55%) and 101 males; 126 had previous HL ( 56%) and 99 nHL.The median age at cardiovascular disease detection was 54 years (range 20-83). The median time between diagnosis of lymphoma and diagnosis of cardiovascular diseases was 14 years (range 0-43).The most common cardiac disturbances described were valvulopathies of different type and grade (95), arterial hypertension (76) and ischemic cardiopathy (32); some patients had more than one alteration. Moreover 77 out patients showed a diastolic relaxation abnormality without ventricular dysfunction which whose the only alteration detected in 33 cases.In 114 patient abnormalities were first detected during screening in asymptomatic condition: in fact we had planned electrocardiographic and echocardiografic evaluation in 206 patients without known cardiological problems.One hundred fourteen out of 206 screened (55%) showed previous unknown cardiac disturbance.Regarding the previous therapies: mediastinal radiotherapy had been administered in 64 of patients with valvulopathies (and in all with only calcification) (67%), in 13 with ischemic cardiopathies (41%) and in 33 with diastolic relaxation abnormality (43%); chemotherapy antracycline-based had been receveid by 77 with valvulopathies (81%), by 19 with ischemic cardiopathies (60%) and by 73 with diastolic relaxation abnormality (95%).
Conclusion
Our analysis confirms that a high percentage of patient survived to lymphomas can develop cardiovascular diseases and outline the importance of cardiac surveillance.Their monitoring would be promote because can detect asymptomatic structural and functional anomalies as diastolic relaxation abnormality considered an early sign of cardiomyopathies.
Session topic: E-poster
Type: Publication Only
Background
Improvements in the treatment of Lymphomas have resulted in an increasing number of long term survivors. This patient’s population is at risk of developing late therapy related complications that can negatively affect their survival and quality of life.
Aims
In our institution since September 2014 the Hodgkin’s (HL) and aggressive non Hodgkin’s Lymphomas (nHL) long term survivors are followed up in a dedicated clinic aimed to detect long term clinical problems that can affect people undergone previous radiation therapy and/or chemotherapy.
Methods
We had planned electrocardiographic and echocardiografic evaluation in patients without known cardiological problems.
Results
We have analyzed data regarding consecutive 469 patients coming in our clinic from 15 September 2014 to 18 February 2016, 247 have been treated for HL and 222 for nHL. Two hundred thirty three were females, 236 males; median of age at diagnosis was 29 years for HL (13-84), 48 years for nHL (12-83); median of age at last observation in the follow up clinic was 50 years for HL (range 21-89) and 62 years for nHL (range 24-88). The median of duration of follow up was 18 years for HL (range 5-40) and 13 years for nHL (range 5-37). Thirty seven of our patients had cardiovascular disorders before the diagnosis of lymphoma.The cardiac function has been studied in three hundred sixty one of our patients.Two hundred twenty five out of 361 (62%) developed cardiac abnormalities of different type and severity in the period following treatment for their lymphoma (Table 1). They were 124 females (55%) and 101 males; 126 had previous HL ( 56%) and 99 nHL.The median age at cardiovascular disease detection was 54 years (range 20-83). The median time between diagnosis of lymphoma and diagnosis of cardiovascular diseases was 14 years (range 0-43).The most common cardiac disturbances described were valvulopathies of different type and grade (95), arterial hypertension (76) and ischemic cardiopathy (32); some patients had more than one alteration. Moreover 77 out patients showed a diastolic relaxation abnormality without ventricular dysfunction which whose the only alteration detected in 33 cases.In 114 patient abnormalities were first detected during screening in asymptomatic condition: in fact we had planned electrocardiographic and echocardiografic evaluation in 206 patients without known cardiological problems.One hundred fourteen out of 206 screened (55%) showed previous unknown cardiac disturbance.Regarding the previous therapies: mediastinal radiotherapy had been administered in 64 of patients with valvulopathies (and in all with only calcification) (67%), in 13 with ischemic cardiopathies (41%) and in 33 with diastolic relaxation abnormality (43%); chemotherapy antracycline-based had been receveid by 77 with valvulopathies (81%), by 19 with ischemic cardiopathies (60%) and by 73 with diastolic relaxation abnormality (95%).
Conclusion
Our analysis confirms that a high percentage of patient survived to lymphomas can develop cardiovascular diseases and outline the importance of cardiac surveillance.Their monitoring would be promote because can detect asymptomatic structural and functional anomalies as diastolic relaxation abnormality considered an early sign of cardiomyopathies.
Session topic: E-poster
{{ help_message }}
{{filter}}